NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, Forecast & News

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals Inc (NASDAQ:ALNA) issued its earnings results on Wednesday, November, 13th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.08. View Allena Pharmaceuticals' Earnings History.

Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Allena Pharmaceuticals.

4 brokerages have issued 1 year price objectives for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $31.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.

Headlines about ALNA stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Allena Pharmaceuticals.

Allena Pharmaceuticals saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 553,300 shares, a decline of 10.2% from the January 15th total of 616,200 shares. Based on an average trading volume of 469,700 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.9% of the company's stock are short sold. View Allena Pharmaceuticals' Current Options Chain.

Some companies that are related to Allena Pharmaceuticals include Verona Pharma (TARA), CASI Pharmaceuticals (CASI), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Brainstorm Cell Therapeutics (BCLI), Solid Biosciences (SLDB), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC) and Surface Oncology (SURF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Amarin (AMRN), Clearside Biomedical (CLSD), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Adamas Pharmaceuticals (ADMS) and Anavex Life Sciences (AVXL).

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.03%), Geode Capital Management LLC (0.45%), Wedbush Securities Inc. (0.21%), Banco Bilbao Vizcaya Argentaria S.A. (0.16%), Algert Global LLC (0.16%) and Goldman Sachs Group Inc. (0.14%). View Institutional Ownership Trends for Allena Pharmaceuticals.

ALNA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Allena Pharmaceuticals.

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, Banco Bilbao Vizcaya Argentaria S.A., Algert Global LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Allena Pharmaceuticals.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNA stock can currently be purchased for approximately $2.16.

Allena Pharmaceuticals has a market capitalization of $50.70 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals.

The official website for Allena Pharmaceuticals is http://www.allenapharma.com/.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.